Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –- Topline data ...